Zhihang Shen

Dr. Zhihang Shen


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2025 in ACS Omega
Verified
Journal Article
Open access
ZSZhihang Shen
Zhihang Shen
GSGustavo Seabra
Gustavo Seabra
JBJason Brant
Jason Brant
KSKalyanee Shirlekar
Kalyanee Shirlekar
Loic P DeleyrolleLoic P Deleyrolle
Loic P Deleyrolle
CLChenglong Li
Chenglong Li
Protein arginine methyltransferase 5 (PRMT5), which symmetrically dimethylates cytosolic and nuclear proteins, has been demonstrated as an important cancer therapeutic target. In recent years, many advanced achievements in PRMT5 inhibitor development have been made. Most PRMT5 inhibitors in the clinical trial focus on targeting the C-terminal catalytic domain, whereas developing small molecules to interrupt the PRMT5/pICLn (methylosome subunit) protein-protein interface is also of great importance for inhibiting PRMT5. Here, we describe a machine-learning-based virtual screening method and use this novel pipeline to screen small-molecule inhibitors of the PRMT5/pICLn interaction. 18 compounds were manually selected for experimental testing. One compound, Z319334062, showed surface plasmon resonance-binding affinity to the target (K D = 21.5 μM) and dose-dependently inhibited symmetric dimethylation levels in patient-derived glioblastoma cell lines.

9 September 2025 in Processes
Verified
Journal Article
Open access
PDF file
ZSZhihang Shen
Zhihang Shen
CLChenglong Li
Chenglong Li
Epigenetic dysregulation is a hallmark of tumorigenesis, with arginine methylation—a post-translational modification—emerging as a key regulatory mechanism in cancer biology. This modification, catalyzed by protein arginine methyltransferases (PRMTs), influences critical cellular processes, including proliferation, differentiation, transcription, RNA splicing, DNA repair, and immune signaling. Among the PRMT family, PRMT5 has garnered significant attention due to its elevated expression across various solid tumors and hematological malignancies, and its strong association with poor clinical outcomes. Notably, PRMT5 exhibits a unique vulnerability in methyl-thio-adenosine phosphorylase (MTAP)-deficient cancers, making it an attractive therapeutic target. Recent advances have led to the development of several PRMT5 inhibitors with diverse binding modes, some of which have progressed into clinical trials for advanced cancers. This review provides a structural and mechanistic overview of PRMT5, summarizes current inhibition strategies, and discusses the challenges and future directions in targeting PRMT5 for cancer therapy.

24 April 2025 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ZSZhihang Shen
Zhihang Shen
GSGustavo Seabra
Gustavo Seabra
CLChenglong Li
Chenglong Li

29 May 2025 in ACS Chemical Biology
Verified
Journal Article
Closed access
ZSZhihang Shen
Zhihang Shen
XYXiaozhi Yang
Xiaozhi Yang
GSGustavo Seabra
Gustavo Seabra
XXXueyong Xu
Xueyong Xu
JDJiawei Dong
Jiawei Dong
CLChenglong Li
Chenglong Li

30 January 2024 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
VRVajja Krishna Rao
Vajja Krishna Rao
SPSubarno Paul
Subarno Paul
MGMitchell Gulkis
Mitchell Gulkis
ZSZhihang Shen
Zhihang Shen
HNHaritha Nair
Haritha Nair
SGSankar K. Guchhait
Sankar K. Guchhait
In this study, a unique strategy of scaffold-hopping-based molecular editing of a bioactive agent NSC-666719 was investigated, which led to the development of new benzodithiazinedioxide-guanidine based anticancer agents with Polβ inhibition.

23 March 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
JSJordan Stokes
Jordan Stokes
IHIram Hyder
Iram Hyder
ZSZhihang Shen
Zhihang Shen
PRPeter Ramdhan
Peter Ramdhan
ABAllison Bayer
Allison Bayer
SSSihong Song
Sihong Song
Studies have shown that IL-10 has therapeutic potential for inflammatory diseases. However, it is challenging to use IL-10 as a therapeutic drug because it also possesses pro-inflammatory functions. To reduce these pro-inflammatory effects of IL-10, we have designed three IL-10 mutants using structure-based computational design technology. We demonstrated that these mutants exhibited significantly lower activity in IL-10-responsive cell lines than wild-type IL-10. Using recombinant adeno-associated virus (rAAV8) vectors expressing wild-type or mutant IL-10 molecules, we performed gene therapy experiments in IL-10 KO mice. The results showed that our vectors mediated high levels of transgene expression. Importantly, IL-10 gene therapy increased body weight gain, reduced colon injury, and prevented the development of inflammatory bowel disease (IBD). Moreover, IL-10 mutant gene therapy elicited significantly lower stimulation of CD8 T and NK cells compared with the wild-type IL-10 group. In summary, our IL-10 mutants provide a protective effect comparable to wild-type IL-10 in the IL-10 KO mouse model, suggesting that they may potentially have reduced pro-inflammatory function. While rigorous investigations of safety and efficacy in different disease models will be required, these results indicate the therapeutic potential of IL-10 mutant gene therapy for inflammatory diseases such as IBD.